Render Target: SSR
Render Timestamp: 2024-11-14T22:49:10.233Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-04-25 20:37:06.276
Product last modified at: 2024-06-07T08:00:16.132Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

IL-6 (Siltuximab Biosimilar) Human mAb #52897

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG1 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    IL-6 (Siltuximab Biosimilar) Human mAb is a biosimilar antibody for Siltuximab. Siltuximab is an FDA-approved human monoclonal antibody directed against IL-6. Siltuximab may help reduce inflammation and stop the growth of cancer cells or abnormal blood cells.
    Endotoxin <0.1 EU/μg of antibody

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free.

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    IL-6 (Siltuximab Biosimilar) Human mAb was confirmed to bind to its intended target protein IL-6 using bio-layer interferometry.

    Species Reactivity:

    Human

    Source / Purification

    IL-6 (Siltuximab Biosimilar) Human mAb is produced at Cell Signaling Technology. Siltuximabb is an antibody directed against human IL-6.

    Background

    Interleukin-6 (IL-6) is a pleiotropic cytokine with central roles in immune regulation, inflammation, hematopoiesis, and oncogenesis. Its biological activities are shared by other IL-6 family members, such as leukemia inhibitory factor and oncostatin M (1). To exert its biological effects, IL-6 must bind to the IL-6 receptor (IL-6R), composed of two alpha chains (IL-6Rα, 80 kDa) and two beta chains (IL-6Rβ or gp130, 130 kDa). Two moieties of IL-6 and two pairs of these receptor chains form a functional hexameric IL-6R complex. The subsequent intracellular signaling events are activated via gp130, which is the common signal transducer of cytokines related to IL-6. Activation of the IL-6R stimulates at least three major signaling pathways: JAK/STAT, PI-3 kinase, and MAPK signaling pathways (2,3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.